Furthermore, the inhibition of hepatic serotonin receptor 2A (HTR2A) signaling in vivo by blocking the synthesis of 5-HT improves liver steatosis [28], as well as hyperglycemia and dyslipidemia [30]. The gene discussed is HTR2A; the disease is fatty liver disease.